RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability

被引：0
|
作者：
Ernest Nadal
Hidehito Horinouchi
Jin-Yuan Shih
Kazuhiko Nakagawa
Martin Reck
Edward B. Garon
Yu-Feng Wei
Jens Kollmeier
Bente Frimodt-Moller
Emily Barrett
Olga Lipkovich
Carla Visseren-Grul
Silvia Novello
机构：
[1] Catalan Institute of Oncology,Faculty of Medicine
[2] IDIBELL,Department of Oncology
[3] L’Hospitalet,undefined
[4] National Cancer Center Hospital,undefined
[5] National Taiwan University Hospital,undefined
[6] Kindai University,undefined
[7] LungenClinic,undefined
[8] Airway Research Center North,undefined
[9] German Center for Lung Research,undefined
[10] David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network,undefined
[11] E-Da Cancer Hospital,undefined
[12] I-Shou University,undefined
[13] Helios Klinikum Emil von Behring,undefined
[14] Eli Lilly and Company,undefined
[15] Eli Lilly and Company,undefined
[16] Eli Lilly and Company,undefined
[17] Lilly Oncology,undefined
[18] University of Turin,undefined
[19] A.O.U. San Luigi Gonzaga,undefined
来源：
Drug Safety | 2022年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：45 / 64
页数：19
相关论文
共 50 条
  • [21] EVEROLIMUS PLUS ERLOTINIB VERSUS ERLOTINIB ALONE IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Bennouna, J.
    Besse, B.
    Leighl, N. B.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 140 - 140
  • [22] Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY (vol 111, pg 4510, 2020)
    Nishio, Makoto
    Seto, Takashi
    Reck, Martin
    Garon, Edward B.
    Chiu, Chao-Hua
    Yoh, Kiyotaka
    Imamura, Fumio
    Park, Keunchil
    Shih, Jin-Yuan
    Visseren-Grul, Carla
    Frimodt-Moller, Bente
    Zimmermann, Annamaria
    Homma, Gosuke
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    CANCER SCIENCE, 2021, 112 (05) : 2064 - 2064
  • [23] RELAY plus , an Exploratory Study of Gefitinib with Ramucirumab in Untreated Patients with EGFR Mutation-Positive Metastatic NSCLC
    Nishio, M.
    Nishio, K.
    Suzukawa, K.
    Omori, Y.
    Enatsu, S.
    Visseren-Gru, C.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S896 - S896
  • [24] Randomized, Double-Blind Study of Erlotinib Plus Ramucirumab or Placebo in First Line for Patients with EGFR Mutation-Positive Metastatic NSCLC
    Polit, R. R.
    Reck, M.
    Juan Vidal, O.
    Nadal, E.
    Lee, P.
    Alexandris, E.
    He, S.
    Nakagawa, K.
    Garon, E. B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1577 - S1577
  • [25] Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
    Nakagawa, Kazuhiko
    Garon, Edward B.
    Seto, Takashi
    Nishio, Makoto
    Aix, Santiago Ponce
    Paz-Ares, Luis
    Chiu, Chao-Hua
    Park, Keunchil
    Novello, Silvia
    Nadal, Ernest
    Imamura, Fumio
    Yoh, Kiyotaka
    Shih, Jin-Yuan
    Au, Kwok Hung
    Moro-Sibilot, Denis
    Enatsu, Sotaro
    Zimmermann, Annamaria
    Frimodt-Moller, Bente
    Visseren-Grul, Carla
    Reck, Martin
    LANCET ONCOLOGY, 2019, 20 (12): : 1655 - 1669
  • [26] First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
    Thierry Landre
    Gaetan Des Guetz
    Kader Chouahnia
    Boris Duchemann
    Jean-Baptiste Assié
    Christos Chouaid
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 3333 - 3339
  • [27] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
    Jung, Hyun Ae
    Woo, Sook Young
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 1749 - +
  • [28] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
    Azuma, Koichi
    Hirashima, Tomonori
    Yamamoto, Nobuyuki
    Okamoto, Isamu
    Takahashi, Toshiaki
    Nishio, Makoto
    Hirata, Taizo
    Kubota, Kaoru
    Kasahara, Kazuo
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Nakanishi, Kaoru
    Akinaga, Shiro
    Nishio, Kazuto
    Mitsudomi, Tetsuya
    Nakagawa, Kazuhiko
    ESMO OPEN, 2016, 1 (04)
  • [29] Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong
    Lee, Vivian W. Y.
    Schwander, Bjoern
    Lee, Victor H. F.
    HONG KONG MEDICAL JOURNAL, 2014, 20 (03) : 178 - 186
  • [30] Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
    Ricciardi, Serena
    Tomao, Silverio
    de Marinis, Filippo
    LUNG CANCER-TARGETS AND THERAPY, 2011, 2 : 1 - 9
12345